Atezolizumab results posted for newly diagnosed glioblastoma trial

ClinicalTrials.gov posted results on 23 September 2026 for a Phase I/II trial of atezolizumab with temozolomide and radiation therapy in newly diagnosed glioblastoma. The completed study enrolled 60 participants; posted results reported median overall survival of 18 months.

Background

The trial evaluated atezolizumab in combination with temozolomide and radiation therapy for patients with newly diagnosed glioblastoma. The listed conditions also included gliosarcoma. The registry summary describes atezolizumab as a monoclonal antibody immunotherapy that may help the immune system attack cancer and interfere with tumor-cell growth and spread. It describes temozolomide as chemotherapy that can stop tumor cells from growing, dividing, or spreading. The supplied record does not provide information about prior approvals or disease prevalence.

Trial design

This completed Phase I/II trial, identified as NCT03174197, enrolled 60 participants. Its listed interventions were atezolizumab and temozolomide, with radiation therapy included in the study regimen described in the title and summary. The record lists no primary-outcome entries and does not identify a comparator arm. Posted measurements included overall survival and dose-limiting toxicities in the Phase I and Phase II portions.

Key results

Median overall survival for the Phase I and Phase II group was 18 months. The record labels a 95% confidence interval for this measurement but supplies no interval value. For dose-limiting toxicities, the registry recorded 1 participant in Phase I and 0 participants in Phase II. No p-values or other outcome analyses were supplied.

What this means

The posted record provides a median overall-survival estimate and counts of participants with dose-limiting toxicities, but it does not establish how the regimen compared with another treatment. The absence of primary-outcome entries, a comparator arm, and a numerical confidence interval limits interpretation of the survival result. The supplied data also do not provide enough detail to assess outcomes by participant characteristics or to draw conclusions about efficacy relative to standard care.

Source

Source: ClinicalTrials.gov, registry results for “Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma,” posted 23 September 2026. Available at clinicaltrials.gov/study/NCT03174197.